Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

被引：0
|
作者：
Swords, Ronan T. [1 ]
Savona, Michael R. [2 ]
Maris, Michael B. [3 ]
Erba, Harry P. [4 ]
Berdeja, Jesus G. [5 ]
Foran, James M. [6 ]
Hua, Zhaowei [7 ]
Faessel, Helene M. [7 ]
Dash, Ajeeta B. [7 ]
Sedarati, Farhad [7 ]
Dezube, Bruce J. [7 ]
Medeiros, Bruno C. [8 ]
机构：
[1] Univ Miami Hosp, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Colorado Blood Canc Inst, Denver, CO USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Mayo Clin, Jacksonville, FL 32224 USA
[7] Takeda Pharmaceut Int Co, Cambridge, MA USA
[8] Stanford Univ, Stanford, MA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 21 条
  • [1] FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL
    Swords, R. T.
    Savona, M. R.
    Maris, M. B.
    Erba, H. P.
    Hua, Z.
    Faessel, H.
    Blakemore, S. J.
    Sedarati, F.
    Dezube, B. J.
    Medeiros, B. C.
    HAEMATOLOGICA, 2014, 99 : 223 - 224
  • [2] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Bixby, Dale L.
    Altman, Jessica K.
    Maris, Michael
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Sedarati, Farhad
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 534 - 543
  • [3] THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML)
    Carew, J.
    Swords, R.
    Kelly, K.
    Smith, P.
    Garnsey, J.
    Mahalingam, D.
    Medina, E.
    O'Dwyer, M.
    Oberheu, K.
    Nawrocki, S.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 183 - 183
  • [4] MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study
    DeAngelo, Daniel J.
    Erba, Harry P.
    Maris, Michael B.
    Swords, Ronan T.
    Anwer, Faiz
    Altman, Jessica K.
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Dezube, Bruce J.
    Medeiros, Bruno C.
    BLOOD, 2013, 122 (21)
  • [5] Results of a Clinical Study of Pevonedistat (Pev),a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)
    Swords, Ronan T.
    Coutre, Steven
    Maris, Michael B.
    Zeidner, Joshua F.
    Foran, James M.
    Cruz, Jose C.
    Erba, Harry P.
    Berdeja, Jesus G.
    Tam, Wayne
    Vardhanabhuti, Saran
    Dobler, Iwona
    Faessel, Helene M.
    Dash, Ajeeta B.
    Sedarati, Farhad
    Dezube, Bruce J.
    Savona, Michael R.
    BLOOD, 2016, 128 (22)
  • [6] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (vol 169, pg 534, 2015)
    Swords, R. T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (02) : 294 - 294
  • [7] UPDATED RESULTS FROM A PHASE 2 STUDY OF PRACINOSTAT (P) IN COMBINATION WITH AZACITIDINE (AZA) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Garcia-Manero, G.
    Atallah, E.
    Khaled, S.
    Arellano, M.
    Patnaik, M.
    Esquibel, V.
    Wood, K.
    Medeiros, B.
    HAEMATOLOGICA, 2015, 100 : 216 - 216
  • [8] The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 288 - 288
  • [9] FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
    Cortes, Jorge E.
    Watts, Justin
    Prebet, Thomas
    Schiller, Gary J.
    Lee, Sangmin
    Yang, Jay
    Wang, Eunice S.
    Dinner, Shira
    Ferrell, Paul Brent, Jr.
    Donnellan, Will
    Jonas, Brian A.
    Wei, Andrew H.
    Montesinos, Pau
    Sangerman, Montserrat Arnan
    Kelly, Patrick
    Li, Ping
    Sweeney, Jennifer
    Watson, Courtney
    Mohamed, Hesham
    Baer, Maria R.
    BLOOD, 2018, 132
  • [10] Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial
    Wei, Andrew H.
    Doehner, Hartmut
    Sayar, Hamid
    Ravandi, Farhad
    Montesinos, Pau
    Dombret, Herve
    Selleslag, Dominik
    Porkka, Kimmo
    Jang, Jun-Ho
    Skikne, Barry
    Beach, C. L.
    Prebet, Thomas
    Zhang, George
    Risueno, Alberto
    Ugidos, Manuel
    See, Wendy L.
    Menezes, Daniel
    Roboz, Gail J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : E84 - E87
123